(Q34536515)

2 August 2017

1 reference

title

Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects (English)

1 reference

2 August 2017

1 reference

1 reference

Guntram Schernthaner

1

1 reference

2 August 2017

publication date

1 August 2003

1 reference

2 August 2017

1 reference

2 August 2017

volume

52

1 reference

2 August 2017

issue

8 Suppl 1

1 reference

2 August 2017

page(s)

29-34

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Impact of dosage frequency on patient compliance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Acute and steady-state insulin responses to glucose in nonobese diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Pathogenesis of NIDDM. A balanced overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Does gliclazide stimulate first-phase, second-phase, or both phases of insulin release?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide potentiates suppression of hepatic glucose production in non—insulin-dependent diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

ATP-sensitive K+ channels and insulin secretion: their role in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Structural basis for the interference between nicorandil and sulfonylurea action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Endothelium: the main actor or choreographer in the remodelling of the retinal microvasculature in diabetes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide: a general free radical scavenger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

In vitro and in vivo antioxidant properties of gliclazide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Antiaggregatory activity of hypoglycaemic sulphonylureas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900215-4

10.1016/S0026-0495(03)00215-4

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference